Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)

NCT03291288 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Drug Interaction Potential

Interventions

DRUG: Tolbutamide
DRUG: Midazolam
DRUG: Pexidartinib

Sponsor

Daiichi Sankyo